Cancer Immunotherapy Consulting

Prof. Dr.med. Christian Blank-de Hoop, MBA

Full Curriculum vitae

Personal data

Name: Prof. Dr. Christian Ulrich Blank

Date of birth: 03.08.1972

Place of birth: Berlin-West

Nationality: German

 

Present position:

Founder of Blank-de Hoop Consultancy

Staff member Medical Oncology and

Staff Scientist Division of Immunology

at the Netherlands Cancer Institute

 

Titles:

MBA (DLMBA, Warwick, UK)

Internal Medicine

Medical Oncologist/Haematologist

Professor (University of Regensburg, Germany)

 

Consultancy References:

Advisor for Freshfields Bruckhaus Deringer in patent lawsuits

Advisor for marketing agencies, e.g. SamHealth NL, Navigate Consulting UK, KeyQuest Health USA

Advisor for BMS, MSD, Roche, GSK, Pfizer, Novartis, Medimmune on national and global level

Advisor Dutch melanoma patients advocacy group

Teaching basics in cancer immunotherapy for BMS, MSD, GSK, Pfizer

 

Research and Clinical Institution:

The Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital

Departments:Department of Medical Oncology, Division of Immunology

Plesmanlaan 121, 1066CX Amsterdam, The Netherl spee

 

Education

1978-1982 Elementary school

1982-1991 Grammar school (Gymnasium)

1991-1992 Military service

1992-1994 Medical school University of Regensburg, Germany, Internship Casualty Department St. Luke’s Hospital, Valletta, Malta

1994-1997 Medical school University of Munich (TUM), Germany

1997-1998 Practical year (Junior house officer) at Department of Cardiology and the Department of Radiology at the University Clinic Munich Rechts der Isar, Germany, A&E Department Royal Infirmary of Edinburgh, UK, and A&E University of Birmingham

1998-2000 Arzt im Pratikum (AiP, internship years) at Department Haematology/ Oncology, University Clinic Regensburg

1999 A&E specialization

2001-2003 Post-Doc, University of Chicago, USA, grant by the National Academy of Science Leopoldina

2001-2006 Master of Business Administration (MBA), distance learning at the University of Warwick, UK

2003-2007 specialist training internal medicine and haematology/oncology at University Clinic Regensburg

2007 Specialist registration internal medicine

2009 Specialist registration haematology/oncology

2010 GCP registration (re-registration 12/2012, 7/2014 and 11/2015)

Clinical Work

1998-2001 Physician at the Department of Haematology and Oncology, University of

Regensburg (rotations H/O, GE, rheumatology, endocrinology, hepatology)

2003-2007 Physician at the Department of Haematology and Oncology, University of

Regensburg (rotations H/O, cardiology, pulmonology, nephrology, intensive care, A&E, ultrasound, bone marrow diagnostics, transfusion medicine, H/O outpatients clinic)

2006-2008 Emergency physician at the University Clinic of Regensburg

since 2007 Physician at the Department of Medical Oncology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital (NKI-AVL), outpatients clinic with focus on melanoma and RCC patients

since 2010 Privatdozent (university lecturer) at the University of Regensburg

since 2015 Professor at the Hematology/Medical Oncology Department, University of Regensburg

 

Basic Research

1994-1997 Doctoral thesis at the Department for Medical Microbiology, Immunology and Hygiene, Technical University Munich, Germany, headed by prof. Hermann Wagner, awarded summa cum laude

2001-2003 Research Fellowship (post-doc) at the Department of Medicine, Section Haematology/Oncology, University of Chicago, USA, lab of prof. Thomas Gajewski

2003 - 2007 Research group leader at the University of Regensburg, Department Haematology/Oncology,

since 2007 Research Group leader, NKI-AVL, Department of Immunology, Amsterdam

 

Memberships

German Society of Biochemistry and Molecular Biology (1993-2006)

German Society of Internal Medicine (1999-2013)

German Society of Immunology (2000-2007)

German Society of Haematology/Oncology (2004-2013)

Dutch Society of Internal Medicine (since 2008)

Dutch Society of Oncology (since 2010)

European Society for Medical Oncology, ESMO (since 2010)

American Society of Oncology, ASCO (since 2010)

 

Honours and awards

1999 Doctor of medicine, summa cum laude

2000 Promotionspreis Faculty of medicine TUM

2003 Travel Award UCCRC Immunology Program

2004 Helga-Reifert-Award for experimental cancer research

2005 Keystone Symposia Scholarship Award

2011 Habilitation and award of Privatdozent (university lecturer) at the University of Regensburg

2015 Professor at the University of Regensburg, Department Hematology and Medical Oncology

 

Teaching & lecturing

2007-present lecturer, assistant physician courses, NKI-AVL, Amsterdam

2011-present lecturer, haematology/oncology courses, Medical School, University of Regensburg

2013-present lecturer, tumour immunology course, Free university (VU), Amsterdam

 

Clinical Trials Experience

Principal investigator N14OPC, NKI-AVL, phase Ib study (investigator initiated study)

Principal investigator M14GO, NKI-AVL, phase Ib/II study

Sub-investigator M14TIL, NKI-AVL, phase III study, (investigator initiated study)

Principal local investigator M14LOG, NKI-AVL, phase II study

Principal local investigator M13MKI, NKI-AVL, phase III study

Principal local investigator M13MME, NKI-AVL, phase III study

Principal local investigator M13MKM, NKI-AVL, phase II study

Sub-investigator M13NIM, NKI-AVL, phase III study

Sub-investigator M13DTA, NKI-AVL, phase III study

Sub-investigator M12BIC, NKI-AVL, phase III study

Principal investigator N11RFA, NKI-AVL, phase Ib/II study (investigator initiated study)

Principal local investigator M11BRI, NKI-AVL, safety study

Principal local investigator M11MME, NKI-AVL, phase II study

Principal local investigator M10BRA, NKI-AVL, phase III study

Sub-investigator M09BRIM, NKI-AVL, phase III study

Principal local investigator M09RCC, NKI-AVL, extended access study

Sub-investigator M09PSR, NKI-AVL, phase III study

Sub-investigator M07ILS, NKI-AVL, phase II study

Sub-investigator MDX010, NKI-AVL, phase III study

Sub-investigator MDX010, University of Regensburg, phase III study

 

Awarded grants

2003-2004 ReForm-A (Regensburg start-up funding): CU Blank. Negative cotimulation of T cell activation via PD-1/PD-L1/L2 interaction

2004-2007 German Cancer Foundation (DKH): CU Blank. The role of PD-L1 for the negative regulation of tumour specific human CD8+ T cells

2004-2007 German Research Society (DFG): CU Blank. Molecular characterization of homeostatic proliferating CD8+ T cells

2005-2007 Wilhelm Sander Foundation: CU Blank. Immunemodulatory function of PD-L1: Blockade of PD-1 as possible clinical treatment option

2007-2012 Dutch Cancer Society: CU Blank, JBAG Haanen, TNM Schumacher. Blockade of PD-1/PD-L1 interaction to improve T cell mediated immunotherapy of cancer

2010-2011 Start-up funding NKI-AVL: H van Boven, A Bex, CU Blank. Preclinical testing of TIL from RCC patients

2011-201 3 MedImmune grant: CU Blank. Evaluation of combined T cell checkpoint blockade in an induced melanoma model

2011-2013 Melanoma Research alliance: CU Blank. Development of immuno- and molecular combination therapy for human melanoma

2013-2015 Novartis Research Grant: CU Blank. Triple and quadruple targeted therapy in a mouse model of human BRAFV600mut melanoma

 

Publications

 

1. Blank C, Luz A, Bendigs S, Erdmann A, Wagner H, Heeg K. Superantigen and endotoxin synergize in the induction of lethal shock. Eur J Immunol. 1997 Apr;27(4):825-33.

 

2. Lipford GB, Bauer M, Blank C, Reiter R, Wagner H, Heeg K. CpG-containing synthetic oligonucleotides promote B and cytotoxic T cell responses to protein antigen: a new class of vaccine adjuvants. Eur J Immunol. 1997 Sep;27(9):2340-4.

 

3. Blank C, Wagner HM, Hohenleutner U, Andreesen R. Rash and Leukaemia - NEH: paraneoplastic or drug-induced? J Clin Oncol. 2000 Oct 1;18(19):3437-9.

 

4. Hwang KW, Sweatt WB, Brown IE, Blank C, Gajewski TF, Bluestone JA, Alegre ML. Targeted Ligation of CTLA-4 In Vivo by Membrane-Bound Anti-CTLA-4 Antibody Prevents Rejection of Allogeneic Cells. J Immunol. 2002 Jul 15;169(2):633-7.

 

5. Blank C, Brown I, Marks, R, Nishimura H, Honjo T, Gajewski TF. Absense of programmed death receptor 1 alters thymic development and enhances generation of CD4/CD8 double-negative TCR-transgenic T cells. J Immunol. 2003 Nov 1;171(9):4574-81.

 

6. Blank C, Brown I, Peterson AC, Spiotto M, Iwai Y, Honjo T, Gajewski TF. PD-L1/B7H-1 Inhibits the Effector Phase of Tumor Rejection by T Cell Receptor (TCR) Transgenic CD8+ T Cells. Cancer Res. 2004 Feb 1;64(3):1140-5.

 

7. Zha Yy, Blank C, Gajewski TF. Negative regulation of T cell function by PD-1. Crit Rev Immunol. 2004;24(4):229-37.

 

8. Blank C, Gajewski TF, Mackensen A. Interaction of PD-L1 on Tumor cells with PD-1 on Tumor-specific T cells as a Mechanism of Immune Evasion – Implications for Tumor Immunotherapy. Cancer Immunol Immunother. 2005 Apr;54(4):307-14.

 

9. Blank C, Brown I, Kacha AK, Markiewicz MA, Gajewski TF. ICAM-1 contributes to but is not absolutely required for CD8+ T cell-mediated tumor rejection in vivo. J Immunol. 2005 Mar 15;174(6):3416-20.

 

10. Blank C, Mackensen, A. Wie Tumorzellen dem Immunsystem entkommen – PD-1/PD-L1 Interaktion als neuer Mechanismus bei der Tumorresistenz. Journal Onkologie 2006 Jan 18; (5): 36-38

 

11. Blank C, Kuball J, Voelkl S, Wiendl H, Becker B, Walter B, Majdic O, Gajewski TF, Theobald M, Andreesen R, Mackensen A. Blockade of PD-L1 (B7-H1) augments human tumor-specific T cell responses in vitro. Int J Cancer. 2006 Jul 15;119(2):317-27.

 

12. Brown IE, Blank C, Kline J, Kacha AK, Gajewski TF. Homeostatic Proliferation as in isolated variable reverses CD8+ T cell anergy and promotes tumor rejection in vivo. J Immunol. 2006 Oct 1;177(7):4521-9.

 

13. Mühlbauer M, Fleck M, Schütz C, Weiss T, Froh M, Blank C, Schölmerich J, Hellerbrand C. PD-L1 is induced in hepatocytes by viral infection and by interferon-α and -γ and mediates T cell apoptosis. J Hepatol. 2006 Oct;45(4):520-8.

 

14. Gajewski TF, Meng Y, Blank C, Brown I, Kacha A, Kline J, Harlin H. Immune resistance orchestrated by the tumor environment. Immunol Rev. 2006 Oct;213:131-45.

 

15. Blank C, Mackensen A. Contribution of the PD-L1/PD-1 Pathway to T-Cell Exhaustion: Implications for Chronic Infections and Tumor Evasion. Cancer Immunol Immunother. 2007 May;56(5):739-45

 

16. Hart C, Blank C, Krause SW, Andreesen R, and Hennermann B. Ifosfamide, epirubicin, and etoposide (IEV) mobilize peripheral blood stem cells more efficiently than cyclophosphamide/etoposide.

Ann Hematol. 2007 Aug;86(8):575-81

 

17. Brem-Exner BG, Sattler C, Hutchinson JA, Koehl GE, Kronenberg K, Farkas S, Inoue S, Blank C, Knechtle SJ, Schlitt HJ, Fändrich F, Geissler EK. Macrophages driven to a novel state of activation have anti-inflammatory properties in mice. J Immunol. 2008 Jan 1;180(1):335-49.

 

18. Kline J, Brown IE, Zha YY, Blank C, Strickler J, Wouters H, Zhang L, Gajewski TF. Homeostatic proliferation plus regulatory T-cell depletion promotes potent rejection of B16 melanoma. Clin Cancer Res. 2008 May 15;14(10):3156-67.

 

19. Hadrup SR, Bakker AH, Shu CJ, Andersen RS, van Veluw J, Hombrink P, Castermans E, Thor Straten P, Blank C, Haanen JB, Heemskerk MH, Schumacher TN. Parallel detection of antigen-specific T-cell responses by multidimensional encoding of MHC multimers. Nat Methods. 2009 Jul;6(7):520-6.

 

20. Bex A, van der Veldt AA, Blank C, van den Eertwegh AJ, Boven E, Horenblas S, Haanen J. Neoadjuvant sunitinib for surgically complex advanced renal cell cancer of doubtful resectability: initial experience with downsizing to reconsider cytoreductive surgery. World J Urol. 2009 Aug;27(4):533-9.

 

21. Schuster K, Gadiot J, Andreesen R, Mackensen A, Gajewski TF, Blank C. Homeostatic proliferation of naïve CD8+ T cells depends on CD62L/L-selectin-mediated homing to peripheral LN. Eur J Immunol. 2009 Nov;39(11):2981-90.

 

22. Strizzi L, Postovit LM, Margaryan NV, Lipavsky A, Gadiot J, Blank C, Seftor RE, Seftor EA, Hendrix MJ. Nodal as a biomarker for melanoma progression and a new therapeutic target for clinical intervention. Expert Rev Dermatol. 2009;4(1):67-78.

 

23. Bex A, Van der Veldt AA, Blank C, Meijerink MR, Boven E, Haanen JB. Progression of a caval vein thrombus in two patients with primary renal cell carcinoma on pretreatment with sunitinib. Acta Oncol. 2010 May;49(4):520-3.

 

24. Borkner L, Kaiser A, van de Kasteele W, Andreesen R, Mackensen A, Haanen JB, Schumacher TN, Blank C. RNA interference targeting programmed death receptor-1 improves immune functions of tumor-specific T cells. Cancer Immunol Immunother. 2010 Aug;59(8):1173-83.

 

25. Powles T, Kayani I, Blank C, Chowdhury S, Horenblas S, Peters J, Shamash J, Sarwar N, Boletti K, Sadev A, O'Brien T, Berney D, Beltran L, Haanen J, Bex A. The safety and efficacy of sunitinib before planned nephrectomy in metastatic clear cell renal cancer. Ann Oncol. 2011 May;22(5):1041-7.

 

26. Gadiot J, Hooijkaas AI, Kaiser AD, van Tinteren H, van Boven H, Blank C. Overall survival and PD-L1 expression in metastasized malignant Melanoma. Cancer. 2011 May 15;117(10):2192-201.

 

27. Bex A, Larkin J, Blank C. Non-clear cell renal cell carcinoma: how new biological insight may lead to new therapeutic modalities. Curr Oncol Rep. 2011 Jun;13(3):240-8.

 

28. Powles T, Blank C, Chowdhury S, Horenblas S, Peters J, Shamash J, Sarwar N, Boleti E, Sahdev A, O'Brien T, Berney D, Beltran L, Nathan P, Haanen J, Bex A. The outcome of patients treated with sunitinib prior to planned nephrectomy in metastatic clear cell renal cancer. Eur Urol. 2011 Sep;60(3):448-54.

 

29. Bex A, Blank C, Meinhardt W, van Tinteren H, Horenblas S, Haanen J. A phase II study of presurgical sunitinib in patients with metastatic clear-cell renal carcinoma and the primary tumor in situ. Urology. 2011 Oct;78(4):832-7.

 

30. Blank CU, Hooijkaas AI, Haanen JBAG, and Schumacher TNM. Combination of targeted therapy and immunotherapy in melanoma. Cancer Immunol Immunother. 2011 Oct;60(10):1359-71.

 

31. Lankheet NA, Blank CU, Mallo H, Adriaansz S, Rosing H, Schellens JH, Huitema AD, Beijnen JH. Determination of sunitinib and its active metabolite N-desethylsunitinib in sweat of a patient. J Anal Toxicol. 2011 Oct;35(8):558-65.

 

32. Hooijkaas AI, Gadiot J, van Boven H, Blank C. Expression of the embryological morphogen Nodal in stage III/IV melanoma. Melanoma Res. 2011 Dec;21(6):491-501.

 

33. Vogel WV, Guislain A, Kvistborg P, Schumacher TN, Haanen JB, Blank CU. Ipilimumab-induced sarcoidosis in a patient with metastatic melanoma undergoing complete remission. J Clin Oncol. 2012 Jan 10;30(2):e7-e10.

 

34. Grünwald V, Karakiewicz PI, Bavbek SE, Miller K, Machiels JP, Lee SH, Larkin J, Bono P, Rha SY, Castellano D, Blank CU, Knox JJ, Hawkins R, Anak O, Rosamilia M, Booth J, Pirotta N, Bodrogi I; on behalf of the REACT Study Group. An international expanded-access programme of everolimus: Addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy. Eur J Cancer 2012, Feb;48(3):324-32.

 

35. Kaiser AD, Schuster K, Gadiot J, Borkner L, Daebritz H, Schmitt C, Andreesen R, Blank C. Reduced tumor-antigen density leads to PD-1/PD-L1 mediated impairment of partially exhausted CD8(+) T cells. Eur J Immunol. 2012 Mar;42(3):662-71.

 

36. Krönig H, Julia Falchner K, Odendahl M, Brackertz B, Conrad H, Muck D, Hein R, Blank C, Peschel C, Haller B, Schulz S, Bernhard H. PD-1 expression on Melan-A-reactive T cells increases during progression to metastatic disease. Int J Cancer. 2012 May 15;130(10):2327-36.

 

37. Bex A, Etto T, Vyth-Dreese F, Blank C, Griffioen AW. Immunological heterogeneity of the RCC microenvironment: do targeted therapies influence immune response? Curr Oncol Rep. 2012 Jun;14(3):230-9.

 

38. Hauschild A, Grob JJ, Demidov LV, Jouary T, Gutzmer R, Millward M, Rutkowski P, Blank CU, Miller WH Jr, Kaempgen E, Martín-Algarra S, Karaszewska B, Mauch C, Chiarion-Sileni V, Martin AM, Swann S, Haney P, Mirakhur B, Guckert ME, Goodman V, Chapman PB. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2012 Jul 28;380(9839):358-65.

 

39. Mougiakakos D, Okita R, Ando T, Dürr C, Gadiot J, Ichikawa J, Zeiser R, Blank C, Johansson C, Kiessling R. High Expression of GCLC is Associated with Malignant Melanoma of Low Oxidative Phenotype and Predicts a Better Prognosis. Journal of Molecular Medicine. 2012 Aug;90(8):935-44.

 

40. Bot I, Blank CU, Brandsma D. Clinical and radiological response of leptomeningeal melanoma after whole brain radiotherapy and ipilimumab. J Neurol. 2012, Sep;259(9):1976-8.

 

41. Hooijkaas A, Gadiot J, Morrow M, Stewart R, Schumacher T, Blank CU. Selective BRAF inhibition decreases tumor-resident lymphocyte frequencies in a mouse model of human melanoma. Oncoimmunology. 2012 Aug 1;1(5):609-617.

 

42. Hooijkaas AI, Gadiot J, van der Valk M, Mooi WJ, Blank CU. Targeting BRAF(V600E) in an Inducible Murine Model of Melanoma. Am J Pathol. 2012 Sep;181(3):785-94.

 

43. Kaiser AD, Gadiot J, Guislain A, Blank CU. Mimicking homeostatic proliferation in vitro generates T cells with high anti-tumor function in non-lymphopenic hosts. Cancer Immunol Immunother. 2013 Mar 62(3):503-15.

 

44. Ascierto PA, Schadendorf D, Berking C, Agarwala SS, van Herpen CM, Queirolo P, Blank CU, Hauschild A, Beck JT, St-Pierre A, Niazi F, Wandel S, Peters M, Zubel A, Dummer R. MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised open-label phase 2 study. Lancet Oncol 2013 Mar;14(3):249-56.

 

45. Van der Hiel B, Blank CU, Haanen JB, Stokkel MP. Detection of Early Onset of Hypophysitis by 18F-FDG PET-CT in a Patient with Advanced Stage Melanoma Treated with Ipilimumab. Clin Nucl Med. 2013 Apr;38(4): e182-4.

 

46. Bot I, Blank CU, Boogerd W, Brandsma D. Neurological immune-related adverse events of ipilimumab. Pract Neurol. 2013 Aug;13(4):278-80.

 

47. Powles T, Kayani I, Sharpe K, Lim L, Peters J, Stewart GD, Berney D, Sahdev A, Chowdhury S, Boleti E, Shamash J, Reynolds AR, Jones R, Blank C, Haanen J, Bex A. A prospective evaluation of VEGF-targeted treatment cessation in metastatic clear cell renal cancer. Ann Oncol. 2013 Aug;24(8):2098-103.

 

48. Kelderman S, van der Kooij MK, van den Eertwegh AJ, Soetekouw PM, Jansen RL, van den Brom RR, Hospers GA, Haanen JB, Kapiteijn E, Blank CU. Ipilimumab in pretreated metastastic uveal melanoma patients. Results of the Dutch Working group on Immunotherapy of Oncology (WIN-O). Acta Oncol. 2013 Nov;52(8):1786-8.

 

49. Lankheet NA, Huitema AD, Mallo H, Adriaansz S, Haanen JB, Schellens JH, Beijnen JH, Blank CU. The effect of seasonal variation and secretion of sunitinib in sweat on the development of hand-foot syndrome. Eur J Clin Pharmacol. 2013 Dec;69(12):2065-72.

 

50. Linnemann C, Heemskerk B, Kvistborg P, Kluin RJ, Bolotin DA, Chen X, Bresser K, Nieuwland M, Schotte R, Michels S, Gomez-Eerland R, Jahn L, Hombrink P, Legrand N, Shu CJ, Mamedov IZ, Velds A, Blank CU, Haanen JB, Turchaninova MA, Kerkhoven RM, Spits H, Hadrup SR, Heemskerk MH, Blankenstein T, Chudakov DM, Bendle GM, Schumacher TN. High-throughput identification of antigen-specific TCRs by TCR gene capture. Nat Med. 2013 Nov;19(11):1534-41.]

 

51. Gadiot J, Hooijkaas AI, Deken MA, Blank CU. Synchronous BRAFV600E and MEK inhibition leads to superior control of murine melanoma by limiting MEK inhibitor induced skin toxicity. Onco Targets Ther. 2013 Nov 28;6:1649-58.

 

52. Krönig H, Kremmler L, Haller B, Englert C, Peschel C, Andreesen R, Blank CU. Interferon-induced programmed death-ligand 1 (PD-L1/B7-H1) expression increases on human AML blast cells during treatment. Eur J Haematol. 2014 Mar;92(3):195-203.

 

53. Blank C. The perspective of immunotherapy - new molecules and new mechanisms of action in immune modulation. Curr Opin Oncol. 2014 Mar;26(2):204-14.

 

54. Larkin J, Del Vecchio M, Ascierto PA, Krajsova I, Schachter J, Neyns B, Espinosa E, Garbe C, Sileni VC, Gogas H, Miller WH Jr, Mandalà M, Hospers GA, Arance A, Queirolo P, Hauschild A, Brown MP, Mitchell L, Veronese L, Blank CU. Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study. Lancet Oncol. 2014 Apr;15(4):436-44.

 

55. Kelderman S, Heemskerk B, van Tinteren H, van den Brom RR, Hospers GA, van den Eertwegh AJ, Kapiteijn EW, de Groot JW, Soetekouw P, Jansen RL, Fiets E, Furness AJ, Renn A, Krzystanek M, Szallasi Z, Lorigan P, Gore ME, Schumacher TN, Haanen JB, Larkin JM, Blank CU. Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma. Cancer Immunol Immunother. 2014 May;63(5):449-58.

 

56. Sun C, Wang L, Huang S, Heynen GJ, Prahallad A, Robert C, Haanen J, Blank C, Wesseling J, Willems SM, Zecchin D, Hobor S, Bajpe PK, Lieftink C, Mateus C, Vagner S, Grernrum W, Hofland I, Schlicker A, Wessels LF, Beijersbergen RL, Bardelli A, Di Nicolantonio F, Eggermont AM, Bernards R. Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma. Nature. 2014 Apr 3;508(7494):118-22.

 

57. Rutkowski P, Blank C. Dabrafenib for the treatment of BRAF V600-positive melanoma: a safety evaluation. Expert Opin Drug Saf. 2014 Sep;13(9):1249-58.

 

58. Kvistborg P, Philips D, Kelderman S, Hageman L, Ottensmeier C, Joseph-Pietras D, Welters MJ, van der Burg S, Kapiteijn E, Michielin O, Romano E, Linnemann C, Speiser D, Blank C, Haanen JB, Schumacher TN. Anti-CTLA-4 therapy broadens the melanoma-reactive CD8+ T cell response. Sci Transl Med. 2014 Sep 17;6(254):254ra128.

 

59. Müller J, Krijgsman O, Tsoi J, Robert L, Hugo W, Song C, Kong X, Possik PA, Cornelissen-Steijger PD, Foppen MH, Kemper K, Goding CR, McDermott U, Blank C, Haanen J, Graeber TG, Ribas A, Lo RS, Peeper DS. MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma. Nat Commun. 2014 Dec 15;5:5712.

 

60. Blank CU, Enk A. Therapeutic use of anti-CTLA-4 antibodies. Int Immunol. 2015 Jan;27(1):3-10.

 

61. Scholtens A, Geukes Foppen MH, Blank CU, van Thienen JV, van Tinteren H, Haanen JB.Vemurafenib for BRAF V600 mutated advanced melanoma: results of treatment beyond progression. Eur J Cancer. 2015 Mar;51(5):642-52.

 

62. Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, Daud A, Carlino MS, McNeil C, Lotem M, Larkin J, Lorigan P, Neyns B, Blank CU, Hamid O, Mateus C, Shapira-Frommer R, Kosh M, Zhou H, Ibrahim N, Ebbinghaus S, Ribas A; Pembrolizumab versus Ipilimumab in Advanced Melanoma. N Engl J Med. 2015 Jun 25;372(26):2521-32.

 

63. Haanen JB, Thienen Hv, Blank CU. Toxicity patterns with immunomodulating antibodies and their combinations. Semin Oncol. 2015 Jun;42(3):423-8.

 

64. van den Berg JH, Gomez-Eerland R, van de Wiel B, Hulshoff L, van den Broek D, Bins A, Tan HL, Harper JV, Hassan NJ, Jakobsen BK, Jorritsma A, Blank CU, Schumacher TN, Haanen JB. Case Report of a Fatal Serious Adverse Event Upon Administration of T Cells Transduced With a MART-1-specific T-cell Receptor. Mol Ther. 2015 Sep;23(9):1541-50.

 

65. Kemper K, Krijgsman O, Cornelissen-Steijger P, Shahrabi A, Weeber F, Song JY, Kuilman T, Vis DJ, Wessels LF, Voest EE, Schumacher TN, Blank CU, Adams DJ, Haanen JB, Peeper DS. Intra- and inter-tumor heterogeneity in a vemurafenib-resistant melanoma patient and derived xenografts. EMBO Mol Med. 2015 Sep;7(9):1104-18.

 

66. Ribas A, Puzanov I, Dummer R, Schadendorf D, Hamid O, Robert C, Hodi FS, Schachter J, Pavlick AC, Lewis KD, Cranmer LD, Blank CU, O'Day SJ, Ascierto PA, Salama AK, Margolin KA, Loquai C, Eigentler TK, Gangadhar TC, Carlino MS, Agarwala SS, Moschos SJ, Sosman JA, Goldinger SM, Shapira-Frommer R, Gonzalez R, Kirkwood JM, Wolchok JD, Eggermont A, Li XN, Zhou W, Zernhelt AM, Lis J, Ebbinghaus S, Kang SP, Daud A. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol. 2015 Aug;16(8):908-18.

 

67. Guislain A, Gadiot J, Kaiser A, Jordanova ES, Broeks A, Sanders J, van Boven H, de Gruijl TD, Haanen JB, Bex A, Blank CU. Sunitinib pretreatment improves tumor-infiltrating lymphocyte expansion by reduction in intratumoral content of myeloid-derived suppressor cells in human renal cell carcinoma. Cancer Immunol Immunother. 2015 Oct;64(10):1241-50.

 

68. Van Allen EM, Miao D, Schilling B, Shukla SA, Blank C, Zimmer L, Sucker A, Hillen U, Foppen MH, Goldinger SM, Utikal J, Hassel JC, Weide B, Kaehler KC, Loquai C, Mohr P, Gutzmer R, Dummer R, Gabriel S, Wu CJ, Schadendorf D, Garraway LA. Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science. 2015 Oct 9;350(6257):207-11.

 

69. Schreibelt G, Bol KF, Westdorp H, Wimmers F, Aarntzen EH, Duiveman-de Boer T, van de Rakt MW, Scharenborg NM, de Boer AJ, Pots JM, Olde Nordkamp MA, van Oorschot TG, Tel J, Winkels G, Petry K, Blokx WA, van Rossum MM, Welzen ME, Mus RD, Croockewit SA, Koornstra RH, Jacobs JF, Kelderman S, Blank CU, Gerritsen WR, Punt CJ, Figdor CG, de Vries IJ. Effective Clinical Responses in Metastatic Melanoma Patients after Vaccination with Primary Myeloid Dendritic Cells.Clin Cancer Res. 2016 May 1;22(9):2155-66.

 

70. Blank CU, Haanen JB, Ribas A, Schumacher TN. The "cancer immunogram". Science. 2016 May 6;352(6286):658-60.

 

71. Martens A, Wistuba-Hamprecht K, Foppen MG, Yuan J, Postow MA, Wong P, Romano E, Khammari A, Dreno B, Capone M, Ascierto PA, Di Giacomo AM, Maio M, Schilling B, Sucker A, Schadendorf D, Hassel JC, Eigentler TK, Martus P, Wolchok JD, Blank C, Pawelec G, Garbe C, Weide B. Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab. Clin Cancer Res. 2016 Jun 15;22(12):2908-18.

 

72. Geukes Foppen MH, Brandsma D, Blank CU, van Thienen JV, Haanen JB, Boogerd W. Targeted treatment and immunotherapy in leptomeningeal metastases from melanoma. Ann Oncol. 2016 Jun;27(6):1138-42.

 

73. Kemper K, Krijgsman O, Kong X, Cornelissen-Steijger P, Shahrabi A, Weeber F, van der Velden DL, Bleijerveld OB, Kuilman T, Kluin RJ, Sun C, Voest EE, Ju YS, Schumacher TN, Altelaar AF, McDermott U, Adams DJ, Blank CU, Haanen JB, Peeper DS. RAF(V600E) Kinase Domain Duplication Identified in Therapy-Refractory Melanoma Patient-Derived Xenografts. Cell Rep. 2016 Jun 28;16(1):263-77.

 

74. Kroon P, Gadiot J, Peeters M, Gasparini A, Deken MA, Yagita H, Verheij M, Borst J, Blank CU, Verbrugge I. Concomitant targeting of programmed death-1 (PD-1) and CD137 improves the efficacy of radiotherapy in a mouse model of human BRAFV600-mutant melanoma. Cancer Immunol Immunother. 2016 Jun;65(6):753-63.

 

75. Noe A, de Bruijn RE, Blank C, Horenblas S, Haanen J, Bex A. Comparison of pre-treatment MSKCC and IMDC prognostic risk models in patients with synchronous metastatic renal cell carcinoma treated in the era of targeted therapy. World J Urol. 2016 Aug;34(8):1067-72.

 

76. Hoeller C, Michielin O, Ascierto PA, Szabo Z, Blank CU. Systematic review of the use of granulocyte-macrophage colony-stimulating factor in patients with advanced melanoma. Cancer Immunol Immunother. 2016 Sep;65(9):1015-34.

 

77. Wistuba-Hamprecht K, Martens A, Haehnel K, Geukes Foppen M, Yuan J, Postow MA, Wong P, Romano E, Khammari A, Dreno B, Capone M, Ascierto PA, Demuth I, Steinhagen-Thiessen E, Larbi A, Schilling B, Schadendorf D, Wolchok JD, Blank CU, Pawelec G, Garbe C, Weide B. Proportions of blood-borne Vδ1+ and Vδ2+ T-cells are associated with overall survival of melanoma patients treated with ipilimumab. Eur J Cancer. 2016 Sep;64:116-26.

 

78. Deken MA, Gadiot J, Jordanova ES, Lacroix R, van Gool M, Kroon P, Pineda C, Geukes Foppen MH, Scolyer R, Song JY, Verbrugge I, Hoeller C, Dummer R, Haanen JB, Long GV, Blank CU. Targeting the MAPK and PI3K pathways in combination with PD1 blockade in melanoma. Oncoimmunology. 2016 Oct 14;5(12):e1238557.

 

79. Nijenhuis CM, Huitema AD, Marchetti S, Blank C, Haanen JB, van Thienen JV, Rosing H, Schellens JH, Beijnen JH. The Use of Dried Blood Spots for Pharmacokinetic Monitoring of Vemurafenib Treatment in Melanoma Patients. J Clin Pharmacol. 2016 Oct;56(10):1307-12.

 

80. Schadendorf D, Dummer R, Hauschild A, Robert C, Hamid O, Daud A, van den Eertwegh A, Cranmer L, O'Day S, Puzanov I, Schachter J, Blank C, Salama A, Loquai C, Mehnert JM, Hille D, Ebbinghaus S, Kang SP, Zhou W, Ribas A. Health-related quality of life in the randomised KEYNOTE-002 study of pembrolizumab versus chemotherapy in patients with ipilimumab-refractory melanoma. Eur J Cancer. 2016 Nov;67:46-54.

 

81. Brand A, Singer K, Koehl GE, Kolitzus M, Schoenhammer G, Thiel A, Matos C, Bruss C, Klobuch S, Peter K, Kastenberger M, Bogdan C, Schleicher U, Mackensen A, Ullrich E, Fichtner-Feigl S, Kesselring R, Mack M, Ritter U, Schmid M, Blank C, Dettmer K, Oefner PJ, Hoffmann P, Walenta S, Geissler EK, Pouyssegur J, Villunger A, Steven A, Seliger B, Schreml S, Haferkamp S, Kohl E, Karrer S, Berneburg M, Herr W, Mueller-Klieser W, Renner K, Kreutz M. LDHA-Associated Lactic Acid Production Blunts Tumor Immunosurveillance by T and NK Cells. Cell Metab. 2016 Nov 8;24(5):657-671.

 

82. Weide B, Martens A, Hassel JC, Berking C, Postow MA, Bisschop K, Simeone E, Mangana J, Schilling B, Di Giacomo AM, Brenner N, Kähler KC, Heinzerling L, Gutzmer R, Bender A, Gebhardt C, Romano E, Meier F, Martus P, Maio M, Blank CU, Schadendorf D, Dummer R, Ascierto PA, Hospers GA, Garbe C, Wolchok JD. Baseline biomarkers for outcome of melanoma patients treated with pembrolizumab. Clin Cancer Res. 2016 Nov 15;22(22):5487-5496.

 

83. Cairns L, Aspeslagh S, Anichini A, Kyte JA, Blank C, Ascierto P, Rekers N, Straten PT, Awada A. Cancer immunotherapy: from the lab to clinical applications-Potential impact on cancer centres' organisation. Ecancermedicalscience. 2016 Nov 10;10:691.

 

84. Blank C. Biomarkers for outcome upon MAPK inhibition in melanoma. Lancet Oncol. 2016 Dec;17(12):1634-1636.

 

85. McArthur GA, Maio M, Arance A, Nathan P, Blank C, Avril MF, Garbe C, Hauschild A, Schadendorf D, Hamid O, Fluck M, Thebeau M, Schachter J, Kefford R, Chamberlain M, Makrutzki M, Robson S, Gonzalez R, Margolin K. Vemurafenib in Metastatic Melanoma Patients with Brain Metastases: An Open-Label, Single-Arm, Phase 2, Multicentre Study. Ann Oncol. 2016 Dec 19.

 

86. Deken MA, Song JY, Gadiot J, Bins AD, Kroon P, Verbrugge I, Blank CU. Dermal Delivery of Constructs Encoding Cre Recombinase to Induce Skin Tumors in PtenLoxP/LoxP;BrafCA/+ Mice. Int J Mol Sci. 2016 Dec 20;17(12).

 

87. Van der Kooij MK, Joosse A, Speetjens FM, Hospers GA, Bisschop C, de Groot JW, Koornstra R, Blank CU, Kapiteijn E. Anti-PD1 treatment in metastatic uveal melanoma in the Netherlands. Acta Oncol. 2017 Jan;56(1):101-103.

 

88. Nijenhuis CM, Huitema AD, Blank C, Haanen JB, van Thienen JV, Rosing H, Schellens JH, Beijnen JH. Clinical Pharmacokinetics of Vemurafenib in BRAF-Mutated Melanoma Patients. J Clin Pharmacol. 2017 Jan;57(1):125-128.

 

89. Wistuba-Hamprecht K, Martens A, Heubach F, Romano E, Geukes Foppen M, Yuan J, Postow M, Wong P, Mallardo D, Schilling B, Di Giacomo AM, Khammari A, Dreno B, Maio M, Schadendorf D, Ascierto PA, Wolchok JD, Blank CU, Garbe C, Pawelec G, Weide B. Peripheral CD8 effector-memory type 1 T-cells correlate with outcome in ipilimumab-treated stage IV melanoma patients. Eur J Cancer. 2017 Mar;73:61-70.

 

90. Kandolf Sekulovic L, Peris K, Hauschild A, Stratigos A, Grob JJ, Nathan P, Dummer R, Forsea AM, Hoeller C, Gogas H, Demidov L, Lebbe C, Blank C, Olah J, Bastholt L, Herceg D, Neyns B, Vieira R, Hansson J, Rutkowski P, Krajsova I, Bylaite-Bucinskiene M, Zalaudek I, Maric-Brozic J, Babovic N, Banjin M, Putnik K, Weinlich G, Todorovic V, Kirov K, Ocvirk J, Zhukavets A, Kukushkina M, De La Cruz Merino L, Ymeri A, Risteski M, Garbe C. More than 5000 patients with metastatic melanoma in Europe per year do not have access to recommended first-line innovative treatments. Eur J Cancer. 2017 Mar 2;75:313-322.

 

91. Meerveld-Eggink A, Rozeman EA, Lalezari F, van Thienen JV, Haanen JB, Blank CU. Short-term CTLA-4 blockade directly followed by PD-1 blockade in advanced melanoma patients - a single center experience. Ann Oncol. 2017 Apr 1;28(4):862-867

 

92. Blank CU, Larkin J, Arance AM, Hauschild A, Queirolo P, Del Vecchio M, Ascierto PA, Krajsova I, Schachter J, Neyns B, Garbe C, Chiarion Sileni V, Mandalà M, Gogas H, Espinosa E, Hospers GAP, Miller WH Jr, Robson S, Makrutzki M, Antic V, Brown MP. Open-label, multicentre safety study of vemurafenib in 3219 patients with BRAFV600 mutation-positive metastatic melanoma: 2-year follow-up data and long-term responders' analysis. Eur J Cancer. 2017 Jul;79:176-184

 

93. de Bruijn RE, Kuusk T, Noe AP, Blank CU, Haanen JBAG, Hendricksen K, Horenblas S, Bex A. Observation After Cytoreductive Nephrectomy in Patients With Synchronous Not Completely Resected Metastases of Renal Cell Carcinoma. Urology. 2017 Aug 2. pii: S0090-4295(17)30781-1. doi: 10.1016/j.urology.2017.06.048. [Epub ahead of print]

 

94. Schachter J, Ribas A, Long GV, Arance A, Grob JJ, Mortier L, Daud A, Carlino MS, McNeil C, Lotem M, Larkin J, Lorigan P, Neyns B, Blank C, Petrella TM, Hamid O, Zhou H, Ebbinghaus S, Ibrahim N, Robert C. Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). Lancet. 2017 Aug 16. pii: S0140-6736(17)31601-X.

 

95. Mezzadra R, Sun C, Jae LT, Gomez-Eerland R, de Vries E, Wu W, Logtenberg MEW, Slagter M, Rozeman EA, Hofland I, Broeks A, Horlings HM, Wessels LFA, Blank CU, Xiao Y, Heck AJR, Borst J, Brummelkamp TR, Schumacher TNM. Identification of CMTM6 and CMTM4 as PD-L1 protein regulators. Nature. 2017 Sep 7;549(7670):106-110

 

96. Kong X, Kuilman T, Shahrabi A, Boshuizen J, Kemper K, Song JY, Niessen HWM, Rozeman EA, Geukes Foppen MH, Blank CU, Peeper DS. Cancer drug addiction is relayed by an ERK2-dependent phenotype switch. Nature. 2017 Oct 12;550(7675):270-274.

 

97. Rozeman EA, Dekker TJA, Haanen JBAG, Blank CU. Advanced Melanoma: Current Treatment Options, Biomarkers, and Future Perspectives. Am J Clin Dermatol. 2017 Nov 21

 

98. Boshuizen J, Koopman LA, Krijgsman O, Shahrabi A, van den Heuvel EG, Ligtenberg MA, Vredevoogd DW, Kemper K, Kuilman T, Song JY, Pencheva N, Mortensen JT, Foppen MG, Rozeman EA, Blank CU, Janmaat ML, Satijn D, Breij ECW, Peeper DS, Parren PWHI. Cooperative targeting of melanoma heterogeneity with an AXL antibody-drug conjugate and BRAF/MEK inhibitors. Nat Med. 2018 Feb;24(2):203-212

 

99. Geukes Foppen MH, Rozeman EA, van Wilpe S, Postma C, Snaebjornsson P, van Thienen JV, van Leerdam ME, van den Heuvel M, Blank CU, van Dieren J, Haanen JBAG. Immune checkpoint inhibition-related colitis: symptoms, endoscopic features, histology and response to management. ESMO Open. 2018 Jan 13;3(1):e000278

 

100. Geukes Foppen MH, Boogerd W, Blank CU, van Thienen JV, Haanen JB, Brandsma D. Clinical and radiological response of BRAF inhibition and MEK inhibition in patients with brain metastases from BRAF-mutated melanoma. Melanoma Res. 2018 Apr;28(2):126-133

 

101. Eggermont AMM, Blank CU, Mandala M, Long GV, Atkinson V, Dalle S, Haydon A, Lichinitser M, Khattak A, Carlino MS, Sandhu S, Larkin J, Puig S, Ascierto PA, Rutkowski P, Schadendorf D, Koornstra R, Hernandez-Aya L, Maio M, van den Eertwegh AJM, Grob JJ, Gutzmer R, Jamal R, Lorigan P, Ibrahim N, Marreaud S, van Akkooi ACJ, Suciu S, Robert C. Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma. N Engl J Med. 2018 Apr 15. doi: 10.1056/NEJMoa1802357. [Epub ahead of print]

 

102. Tetzlaff MT, Messina JL, Stein JE, Xu X, Amaria RN, Blank C, Van De Wiel B, Ferguson PM, Rawson RV, Ross MI, Spillane AJ, Gershenwald JE, Saw RPM, Mitchell T, Menzies AM, Long GV, Wargo JA, Davies MA, Prieto VG, Taube JM, Scolyer RA. Pathological assessment of resection specimens after neoadjuvant therapy for metastatic melanoma. Ann Oncol. 2018 Jun 25. doi: 10.1093/annonc/mdy226. [Epub ahead of print]

 

103. Lacroix R, Rozeman EA, Kreutz M, Renner K, Blank CU. Targeting tumor-associated acidity in cancer immunotherapy. Cancer Immunol Immunother. 2018 Jul 5. doi: 10.1007/s00262-018-2195-z. [Epub ahead of print]

 

104. Carlino MS, Long GV, Schadendorf D, Robert C, Ribas A, Richtig E, Nyakas M, Caglevic C, Tarhini A, Blank C, Hoeller C, Bar-Sela G, Barrow C, Wolter P, Zhou H, Emancipator K, Jensen EH, Ebbinghaus S, Ibrahim N, Daud A. Outcomes by line of therapy and programmed death ligand 1 expression in patients with advanced melanoma treated with pembrolizumab or ipilimumab in KEYNOTE-006: A randomised clinical trial. Eur J Cancer. 2018 Aug 7;101:236-243. doi: 10.1016/j.ejca.2018.06.034.

 

105. van Dijk N, Funt SA, Blank CU, Powles T, Rosenberg JE, van der Heijden MS. The Cancer Immunogram as a Framework for Personalized Immunotherapy in Urothelial Cancer. Eur Urol. 2018 Sep 28 [Epub ahead of print]

 

106. Blank CU, Rozeman EA, Fanchi LF, Sikorska K, van de Wiel B, Kvistborg P, Krijgsman O, van den Braber M, Broeks A, van Thienen JV, Mallo HA, CNS, Adriaansz S, ter Meulen S, Pronk LM, Grijpink-Ongering LG, Bruining A, M.D., Gittelman R, Warren S, van Tinteren H, Peeper D, Haanen JBAG, van Akkooi ACJ, Schumacher TN. Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma. Nat Med. 2018 Oct 8. [Epub ahead of print]

 

 

 

Presentations

 

1. Christian Blank, Arne Luz, Suse Hausmann, Sylvia Bendigs and Klaus Heeg. Synergistic effect of lipoplysaccharide (LPS) and staphylococcal enterotoxin B (SEB) during initation of septic shock. Presentation, 12. Frühjahrstagung der Deutschen Gesellschaft für Immunologie, Jena, 29.02. - 02.03.1996

 

2. Christian Blank, Hans Neubauer, Klaus Pfeffer, and Klaus Heeg. Resistance of TNF-Rp55 -/- mice to lethal shock induced by endotoxin and superantigen: Analysis of serum cytokine levels. Poster, 27th Annual Meeting of the Deutsche Gesellschaft für Immunologie, Hamburg, 26.09. -28.09.1996

 

3. Christian Blank, Sylvia Bendigs, Peter Hochholzer, Klaus Pfeffer und Klaus Heeg. Synergistische Effekte von Endotoxin und Superantigen beim letalen septischen Schock: Analyse in TNF-Rp55-/- Mäusen und durch Anti-IFN- monoklonale Antikörper. Oral presentation, Minisymposium „Infektion und Immunabwehr“, Burg Rothenfels, 22.11. - 24.11.1996

 

4. Christian Blank. Synergistic effects of SEB and LPS in induction of lethal shock. Invited talk, Howard Hughes Medical Institute and National Jewish Medical and Research Center, Denver (Colorado), 27. März 2000

 

5. Christian Blank, Mary A. Markiewicz, Ian Brown, Aalok K. Kacha, Kwang Woo Hwang, William Sweatt, Maria-Luisa Alegre, and Thomas F. Gajewski. CD28/CTLA-4/B7-1 interactions quantitatively regulate anti-tumor CD8+ T cell responses and can function downstream from initial CTL differentiation. Oral presentation and poster, 30th Autumn Immunology Conference, Chicago (USA), November 17-19, 2001

 

6. Christian Blank. PD-L1 on murine and human tumors and its possible role in tumor evasion. Invited talk, Universitätsklinikum Tübingen, October 1, 2003

 

7. Christian Blank. PD-L1 on murine and human tumors and its possible role in tumor evasion: Implications for adaptive T cell therapies. Invited talk, Klinikum der Johannes Gutenberg-Universität Mainz, December 15, 2003

 

8. Christian Blank. PD-L1 on human tumors and ist possible role in tumor evasion: Implications for adaptive T cell therapies Invited Talk, TU München, München, March 8, 2004

 

9. Christian Blank, Jürgen Kuball, Bernd Becker, Otto Majdic, Heinz Wiendl, Matthias Theobald, Reinhard Andreesen and Andreas Mackensen. Expression of PD-L1 on Human Tumors inhibits Tumor-specific T cell Responses. Oral presentation, DGHO-Meeting, Innsbruck, October 2-6, 2004

 

10. Christian Blank. PD-L1 Expression auf Tumoren und deren Rolle bei der Hemmung tumorspezifischer T-Zellen Invited talk, Leopoldina-Förderprogramm Meeting, Halle/Saale, October 14-15, 2004

 

11. Christian Blank. Koinhibitorische B7-Wege: des einen Freud, des andern Leid. Invited talk, Jahrestagung der Arbeitsgemeinschaft Neuroimmunologie, Kloster Seeon, February 5-6, 2005

 

12. Christian Blank. Immune Evasion by PD-L1/B7-H1 Expression on Tumors. Invited talk. Micromet AG, Munich, April 14 2005

 

13. Christian Blank. Immune Evasion by PD-L1/B7-H1 Expression on Tumors. Invited talk. Tegenero AG, Wuerzburg, June 22 2005

 

14. Christian Blank. Evading from tumorspecific T cells: it’s PD-L1! Invited talk, SFB 643 Meeting, Erlangen, July 19, 2005

 

15. Christian Blank. Lymphopenia-mediated Colitis: It’s Homeostatic Proliferation. Invited talk, GvL-GvHD-Meeting Garmisch-Partenkirchen. January 22-25, 2006

 

16. Christian Blank. Escaping from T cells: it’s PD-L1. Invited talk, CIMT Meeting, Mainz, May 04-05, 2006

 

17. Christian Blank. Escaping from T cells: it’s PD-L1. Invited talk, NKI, Amsterdam, May 29, 2006

 

18. Christian Blank. Inhibitory influence of PD-L1 on T cells: Not the same procedure as everytime. Invited talk, University of Wuerzburg, June 29, 2006

 

19. Christian Blank. The Search for the HP Phenotype. Invited talk, Jahrestagung der Arbeitsgemeinschaft Neuroimmunologie, Kloster Seeon, February 2-4, 2007

 

20. Christian Blank. Inhibition of PD1/PD-L1 Interaction to improve anti-Tumor Immune Responses. Invited talk, SFB 456, Munich 5, 2007

 

21. Christian Blank. Suppression of Anti-Tumor Immunresponses via Coregulatory Mechanisms. Invited talk, DGHO-Meeting 2007, Basel, Switzerland

 

22. Christian Blank. Suppression of Anti-Tumor Immune responses via Coregulatory Mechanisms. Invited talk, University of Utrecht, January 8, 2008

 

23. Christian Blank. Acute Homeostatic Proliferation of Naive CD8+ T Cells depends on CD62L/L-selectin mediated Homing to Intact Peripheral Lymph nodes. Invited talk, University of Erlangen, April 16, 2008

 

24. Christian Blank. Developing a system of in vitro homeostatic proliferation of TCR engineered tumor specific T cells in artificial lymph nodes. Invited talk, Zellwerk GmbH, Berlin, May 28, 2008

 

25. Lisa Borkner, Andreas Mackensen, and Christian Blank. Suppression of the co-inhibitory receptor Programmed Death-1 (PD-1) on tumor-specific T cells via RNA interference. Poster, Keystone Meeting, Salt Lake City, January 11-16, 2009

 

26. Lukas Kremmler and Christian Blank. The Role of PD-1 on MTOC Localization during the Kiss of Death. Poster and oral presentation, Keystone Meeting, Salt Lake City, January 11-16, 2009

 

27. Christian Blank. Combating tumour immune escape PD-L1, PD-1 and friends. Invited talk, MedImmune, Cambridge, January 19, 2010

 

28. Christian Blank. Combating tumour immune escape PD-L1, PD-1 and friends. Invited talk, Jahrestagung der Arbeitsgemeinschaft Neuroimmunologie, Kloster Seeon, February 5-7, 2010

 

29. Andrew Kaiser, Kerstin Schuster, Jules Gadiot, Tasuko Honjo, Henry Daebritz, Clemens Schmitt, Reinhard Andreesen and Christian Blank. Low tumor-antigen density leads to PD-L1/PD-1 mediated suppression of partially exhausted CD8+ T cells. Poster and oral presentation, Keystone Meeting, February 7-12, 2010

 

30. Christian Blank. Combating tumour immune escape PD-L1, PD-1 and friends. Invited talk, TIMO Meeting, Halle, May 6-8, 2010

 

31. Anna Hooijkaas, Jules Gadiot, and Christian Blank. Combined targeted und immunotherapy in an induced mouse melanoma model (from bed back to benchside). Invited talk, TIMO meeting, Halle, April 14-16, 2011

 

32. Christian Blank. Combined targeted und immunotherapy in an induced mouse melanoma model (from bed back to benchside). Invited talk, University of Heidelberg, May 19, 2011

 

33. Christian Blank. Combined targeted and immunotherapy in a mouse model of human melanoma. Invited talk, University of Regensburg, February 22, 2012

 

34. Christian U. Blank. Development of immuno- and molecular combination therapy for human melanoma. Invited talk, Melanoma Research Alliance meeting, Washington, March 1-2, 2012

 

35. Christian Blank. New developments in the treatment of RCC. Oral presentation, mTOR symposium, Utrecht, Mar 07, 2013

 

36. Christian Blank. RCC – Neoadjuvant Therapy. Invited talk, CORE meeting, Vienna, April 11-13, 2013

 

37. Christian Blank. Targeted and Immunotherapy in a mouse model of human BRAF V600E mutation positive melanoma. Invited talk, PIVAC meeting, October 2-4, 2013

 

38. Christian Blank. From Bench to bedside and back - blockade of co-inhibitory molecules for the treatment of malignant melanoma. Invited talk, Annual Meeting German, Austrian, & Swiss Societty for Hematology and Oncology, Vienna, October 18-22, 2013

 

39. Christian Blank. Targeted Therapy of Melanoma. Invited talk, Annual Meeting German, Austrian, & Swiss Societty for Hematology and Oncology, Vienna, October 18-22, 2013

 

40. Christian Blank. Progression in treatment of metastasized melanoma – ipilimumab and immune therapy. Invited talk, University of Utrecht, 2014, Utrecht, January 28

 

41. Christian Blank. Lactate dehydrogenase as selection criterion for ipilimumab treatment &

Neoantigen-specific CD8 T cell responses. Invited talk, IMWG meeting, 2014, Budapest, March 24-25

 

42. Christian Blank. Metastatic melanoma – outlook and future perspectives. Invited talk, Roche satellite symposium EADO 2014, Vilnius, May 6

 

43. Christian Blank. Solid foundations, practical considerations for treatment with ipilimumab. Invited talk, BMS satellite symposium EADO 2014, Vilnius, May 6

 

44. Christian Blank. Lactate dehydrogenase as selection criterion for ipilimumab treatment &

Neoantigen-specific CD8 T cell responses. Invited talk, Perspective in Melanoma Meeting 2014, Dublin, Septemeber 20

 

45. Christian Blank. The science behind combinations with immunotherapy in melanoma - Combining Immunotherapies. Invited plenary talk, ESMO Annual Meeting, 2014, Madrid, September 27

 

46. Christian Blank. Combined BRAF and MEK inhibition- Discussion LBA4_PR and LBA5_PR Invited discussion presidential session, ESMO Annual Meeting, 2014, Madrid, September 27

 

47. Christian Blank. Which Combination of targeted therapies might be best to combine with immunotherapy? Invited talk, EORTC Melanoma Group Meeting, 2014, Rotterdam, October 17

 

48. Christian Blank, Immunotherapy in Melanoma - Lessons from the past and new therapeutic advances. Invited talk, University Brescia, 2014, Brescia, November 3

 

49. Christian Blank. Optimal Use of Targeted Therapy Invited talk, GSK BRAF inhibitor meeting, 2014, Vienna, November 7

 

50. Christian Blank, T cell checkpoint blockade in melanoma – from mouse to man and back. Invited talk, 10th NRCI conference, 2014, Liverpool, November 4

 

51. Christian Blank, Checkpoint remmers bij het gemetastaseerde melanoom. Invited talk, Dutch Working group melanoma (WIN-O) Annual Meeting 2014, Nunspeet, November 27

 

52. Christian Blank, Übertragbarkeit präklinischer Forschung in den klinischen Alltag. Invited talk, BMS KOL meeting, 2014, Hamburg, November 28

 

53. Christian Blank, Melanoom anno 2015, Invited talk, Therapie op Maat Meeting, 2015, Papendal, February 6

 

54. Christian Blank, Melanoom anno 2015, Invited talk, Dutch Surgery Week, 2015, Amsterdam, February 9

 

55. Christian Blank, Optimal Use of Targeted Therapy. Invited talk, Chugai Vemurafenib Japan Initiation, 2015, Tokyo, February 15

 

56. Christian Blank, Systemic therapy of late stage melanoma – it’s not evolution, it’s revolution. Invited talk, MSD European Keytruda Launch Meeting, 2015, Berlin, May 22

 

57. Christian Blank, Emerging I-O data in melanoma, Invited talk, MSD KOL Meeting, 2015, Zurich, June 19

 

58. Christian Blank, Predictive markers for tumor response - anti-PD-1 antibodies, Invited talk, International Post-ASCO Meeting, 2015, Munich, June 25

 

59. Christian Blank, My vision on melanoma therapy 2020, Invited talk, International Post-ASCO Meeting, 2015, Munich, June 26

 

60. Christian Blank, Melanoma, Invited talk, ESMO Academy, 2015, Oxford, August 28-30

 

61. Christian Blank, How to tickle T cells to fight against melanoma? Invited talk, Annual Meeting, German Working Group Dermatooncology (ADO), Munich, September 11

 

62. Christian Blank, Melanoma: Immunotherapy, TKIs, chemotherapy, combinations? What’s next? Invited plenary talk, ECC 2015, Vienna, September 27

 

63. Christian Blank, Proffered Paper Session: Melanoma and Skin Cancer II. Invited discussion session, ECC 2015, Vienna, September 28

 

64. Christian Blank, Immunotherapy of melanoma. Invited talk, Multidisciplinary Immune-Oncology Meeting, Utrecht, November 03, 2015

 

65. Christian Blank, Combination with/of immunotherapies. Invited talk plenary session, AACR-NCI-EORTC Molecular Targets Conference 2015, Boston November 07

 

66. CU Blank. Tumor immunology and Cancer Immunotherapy. Invited talk, ODDP 2016 course, Amsterdam, November 25, 2015

67. Christian Blank, A Braf/Pten Driven Mouse Model of Human Melanoma: Challlenges and Opportunities. Invited talk, Pre-Clinical Models in Immuno-Oncology meeting, Stockholm, February 22, 2016

 

68. Christian Blank, New Checkpoint Targets in Melanoma: Current Status. Invited talk, HemOncToday-Melanoma meeting, New York, March 19, 2016

 

69. Christian Blank, Towards personalized immunotherapy: The Cancer Immunogram. Invited talk, HemOncToday-Melanoma meeting, New York, March 19, 2016

 

70. Christian Blank. Elevated LDH as one of the strongest biomarkers of the Cancer Immunogram. Invited talk, Tumor Metabolism meets Immunology Meeting, Regensburg, April 30, 2016

 

71. Christian Blank, Melanoma – State of the Art 2016. Invited talk, Melanoma regional meeting at Royal Marsdon, London, May 13, 2016

 

72. Christian Blank, Melanoma - systemic treatment. Inivited talk, CWO symposium, Eindhoven, May 20, 2016

 

73. Christian Blank. Biomarkers of immune response. Invited talk, OECI oncology days, Brussels, Juni 15-17, 2016

 

74. Christian Blank. Combined Immune Checkpoint Inhibition. Invited talk, 6th European post-Chiacgo Melanoma/Skin Cancer Meeting, Munich, July 1st, 2016

 

75. Christian Blank, Melanoma, Invited talk, ESMO Academy, 2015, Oxford, August 26-28

 

76. Christian Blank. Strategies to overcome drug resistance in melanoma. Invited presentation, 16th World Congress on Cancers of the Skin and 12th Congress of the European Association of Dermato-Oncology Vienna, September 2nd, 2016

 

77. Christian Blank. Sequencing therapy in melanoma – which options do we have? Invited presentation, 16th World Congress on Cancers of the Skin and 12th Congress of the European Association of Dermato-Oncology Vienna, September 2nd, 2016

 

78. Christian Blank. Combined Therapies for Melanoma – where do we go? Invited presentation, 16th World Congress on Cancers of the Skin and 12th Congress of the European Association of Dermato-Oncology Vienna, September 3rd, 2016

 

79. Christian U Blank, Alexander van Akkooi, Lisette EA Rozeman, Pia Kvistborg, Hans JV van Thienen, Bauke Stegenga, Brian Lamon, John BAG Haanen, Ton NM Schumacher. Neo-)adjuvant ipilimumab + nivolumab (IPI+NIVO) in palpable stage 3 melanoma. Oral presentation LBA 39, ESMO 2016 Copenhagen, Oct 7-11, 2016

 

80. Christian Blank. Mechanisms of Caner Immune Evasion. Invited talk, International Immune Oncology Symposium, Sao Paulo, Oct 22, 2016

 

81. Christian Blank. The Future of Checkpoint Inhibition. Invited talk, International Immune Oncology Symposium, Sao Paulo, Oct 22, 2016

 

82. Christian Blank, Immunotherapy Melanoma, Invited talk, 1st Australasian Immunotherapy Meeting, Sydney, Oct 26-27, 2016

 

83. Christian Blank, Targeting the other cells, Invited talk, 1st Australasian Immunotherapy Meeting, Sydney, Oct 26-27, 2016

 

84. Christian Blank. The Cancer Immunogram: Different aspects of the interaction between cancer and the immune system. Invited talk, ESMO Symposium on Immuno-Oncology, Lausanne, November 6, 2016

 

85. CU Blank, ACJ van Akkooi, L Rozeman, P Kvistborg, H van Thienen, B Stegenga, B Lamon, JBAG Haanen, TNM Schumacher (Neo-)adjuvant ipilimumab + nivolumab (IPI+NIVO) in palpable stage 3 melanoma – initial data from the OpACIN trial. Oral presentation LBA, Society for Melanoma Research 2016 Congress November 6-9, 2016, Boston, Massachusetts

 

86. CU Blank. Biomarkers. Oncology days for Nurses, Ede-Wageningen, Nov 15, 2016

 

87. CU Blank. Essentials of tumor immunology and cancer immunotherapy. Invited talk, ODDP 2016 course, Amsterdam, November 16, 2016

 

88. CU Blank. Safety of the combination of a PD-1 inhibitor (Nivolumab) and a CTLA-4 inhibitor (Ipilimumab) in melanoma. Invited presentation. Norwegian round table meetings. Oslo, Jan 12, 2017

 

89. CU Blank. Immunotherapy: its mechanism and relevance to prostate cancer. Invited talk. Netherlands Prostate Cancer Meeting, Jan 17, 2017

 

90. CU Blank. Clinical experience with immunotherapy. How to manage side-effects. Invited talk, ECCO Annual Meeting, Jan 27-30, 2017

 

91. CU Blank. Phase-I/II study combining ipilimumab with RFA in liver metastasis of uveal melanoma. Invited presentation. Delcath Meeting, Prague, Feb 4, 2017

 

92. CU Blank. Biomarkers. I-O days for Research Nurses, Lunteren, Feb 7, 2017

 

93. CU Blank. Positioning of Immunotherapy for solid tumors. Invited presentation. Boerhave courses for general practioners, Leiden, Feb 09, 2017

 

94. CU Blank. Combining targeted and immunotherapy in melanoma. Why intermittent combination might be the way to go. EACR meeting, Amsterdam, Mar 15, 2017

 

95. CU Blank. (Neo-)adjuvant ipilimumab + nivolumab (IPI+NIVO) in palpable stage 3 melanoma – initial data from the OpACIN trial. Invited talk. BMS II-ON Meeting, Feb 27-28, 2017

 

96. CU Blank. The Cancer Immungram. Invited presentation, Cellular Therapy Meeting, Erlangen, March 17, 2017

 

97. CU Blank. Emerging approaches in melanoma immunotherapy Invited presentation, Royal College of Physicians, London, March 17, 2017

 

98. CU Blank. The Cancer Immungram. Invited talk, Copenhagen, April, 17, 2017

 

99. CU Blank. Update on anti-CTLA1 and anti-PD1 treatment in advanced melanoma-challenging questions. EADO 2017, Athens, May 5, 2017

 

100. CU Blank. Safety of the combination of a PD-1 inhibitor (Nivolumab) and a CTLA-4 inhibitor (Ipilimumab) in melanoma. Invited talk. Sahlgrenska University Hospital, Goteborg, May 12, 2017

 

101. CU Blank. Combining Targeted and Immunotherapy. Invited talk, CRUK Manchester, May 18, 2017

 

102. CU Blank. Immuno-Oncology - “How it all got started…” Invited talk. EUFEMED Meeting, London, May 19, 2017

 

103. CU Blank. Immune Checkpoints - General Overview. ESMO Preceptorship, Amsterdam, May 26-27, 2017

 

104. CU Blank. New biomarkers for response to immunotherapy. Invited talk. ESMO Annual Meeting, Sept 8-12, 2017

 

105. E.A. Rozeman, W. Prevoo, M.A.J. Meier, K. Sikorska, B.A. van de Wiel, A. Broeks, H. van Tinteren, E. Kapiteijn, J.V. Thienen, J.B. Haanen, C.U. Blank. Combined radiofrequency ablation and ipilimumab in uveal melanoma: Results from the SECIRA‐UM trial. Proffered Paper Session, ESMO Annual Meeting, Sept 8-12, 2017

 

106. E.A. Rozeman, L. Fanchi, A.C.J. van Akkooi, T. Kuilman, O. Krijgsman, A Broeks, E. Hooijberg, B van de Wiel, R van der Linden, P. Kvistborg, J.V. van Thienen, B. Stegenga, B. Lamon, J.B. Haanen, T.N.M. Schumacher, C.U. Blank. Proffered Paper Session, ESMO Annual Meeting, Sept 8-12, 2017

 

107. CU Blank. Immunotherapy of Malignant Melanoma. Invited talk. University of Lisbon, Oct 12, 2017

 

108. CU Blank. Determinants of melanoma immunogenicity and escape mechanisms. Invited talk. 2oth Brazilian Clinical Oncology Congress. Rio de Janeiro, Oct 26, 2017.

 

109. CU Blank. Combining Different Forms of Immunotherapy for the Treatment of Melanoma. Invited talk. 2oth Brazilian Clinical Oncology Congress. Rio de Janeiro, Oct 26, 2017

 

110. CU Blank. Future Perspectives with Immunotherapy. Invited talk. 2oth Brazilian Clinical Oncology Congress. Rio de Janeiro, Oct 26, 2017

 

111. CU Blank. Immunotherapy biomarkers: where are we and what is next? Invited talk. 2oth Brazilian Clinical Oncology Congress. Rio de Janeiro, Oct 27, 2017

 

112. CU Blank. Therapie des metastasierten Melanom. Invited talk, Kantonsspital Baden, Nov 3, 2017

 

113. CU Blank. PD-1 blockade and its limitations. Invited talk. ESMO Asia, Nov 18, 2017

 

114. CU Blank. Mechanisms of resistance and biomarkers in immunotherapy. Invited talk. ESMO Asia, Nov 18, 2017

 

115. CU Blank. Die Therapie des metastasierten Melanoms – State-of-the-Art und Ausblick. Invited talk. DWFA Meeting, Cologne, 24. November 2017

 

116. CU Blank. Neoadjuvant immunotherapy as a new treatment Strategy. Invited talk, Annual Meeting Danish Melanoma Group, Oedense, Dec 13, 2017

 

117. CU Bank. Neo-adjuvant versus adjuvant Ipilimumab + Nivolumab in macroscopic stage III melanoma – updated biomarker analysis. Invited talk. BMS II-ON Annual Meeting, Philadelphia, Jan 22, 2018

 

118. CU Blank. Safety of the combination of a PD-1 inhibitor (Nivolumab) and a CTLA-4 inhibitor (Ipilimumab) in melanoma. Invited talk. Uppsala Hospital, Jan 26, 2018

 

119. CU Blank. Biomarkers for neo-adjuvant immunotherapy in melanoma. Invited talk. Cancer Core Europe, Annual Meeting, Paris, Feb 12, 2018

 

120. CU Blank. Acquired immune resistance mechanisms to immunotherapy. Invited talk. BMS R&D days, Marseille, Mar 8-9, 2018

 

121. CU Blank. Neo-adjuvant checkpoint inhibition – the pathway towards personalized immunotherapy. Invited talk. 25th Porto Cancer Meeting, Porto, Apr 26, 2018

 

122. CU Blank. Neo-adjuvant checkpoint inhibition – the pathway towards personalized immunotherapy. Invited talk. ASPIC Meeting, Lisbon, May 11, 2018